CBCT-derived synthetic CT predicted head and neck replanning with 92% sensitivity and specificity
DART predicted clinically triggered head and neck adaptation with 92% sensitivity and specificity using a unified 2-Gy dosimetric threshold.
DART predicted clinically triggered head and neck adaptation with 92% sensitivity and specificity using a unified 2-Gy dosimetric threshold.
In 201 recurrent glioblastomas, 80% required no more than 10.4 mm expansion to encompass 80% of recurrence volume.
Substantial physician-dependent dose variation meant treatment-group assignment did not consistently reflect the dose actually delivered to regional nodes.
Longer survival after metastasis-directed therapy is creating unmet physical, psychological and functional needs that conventional surveillance pathways may not adequately address.
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Hollow 3D-printed proton collimators and compensators were produced within 45 minutes and accurately shaped small experimental proton fields.
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
In eight bulky tumor sites, flattening-filter VMAT lattice radiotherapy produced 75% symptom relief with no grade 3 or higher acute toxicity.
Brainlab Elements commissioning was completed in one day, while Monte Carlo generally agreed with end-to-end measurements within 3%.
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
Across 40 Unity SBRT plans, OCTAVIUS 4D achieved 98.3% mean local gamma passing with sub-degree angular agreement.
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.